Choose injectable BPC-157 if: Your target is a tendon, ligament, joint, or muscle injury You need systemic anti-inflammatory or tissue repair effects Speed and reliability of delivery matter You are working within a structured peptide therapy protocol with a licensed provider Choose oral BPC-157 if: Your primary concern is gut health leaky gut, IBD, IBS, gastric ulcers You want high local GI concentrations, not systemic distribution You prefer non-invasive administration for long-term or maintenance use You are combining BPC-157 with another systemic peptide therapy Consider nasal delivery only if: Neurological applications are the clinical focus A licensed provider explicitly recommends it based on your presentation Injection is contraindicated and oral delivery is insufficient Do not choose a delivery method based on convenience alone
Research supplier reputation in peptide communities
References: Alfaiz, A
BPC-157 promotes angiogenesis, the formation of new blood vessels, through activation of the VEGF pathway
doi:10.1371/journal.pone.0040365 Philippova M, Joshi MB, Pfaff D, Kyriakakis E, Maslova K, Erne P, Resink TJ (2012) T-cadherin attenuates insulin-dependent signalling, eNOS activation, and angiogenesis in vascular endothelial cells
